Corvus Pharmaceuticals(US:CRVS) Globenewswire·2026-01-20 12:00Core Insights - Corvus Pharmaceuticals announced positive results from cohort 4 of the Phase 1 clinical trial for soquelitinib, showing favorable safety and efficacy in patients with moderate to severe atopic dermatitis [1][2][3] - The company plans to initiate a Phase 2 trial in Q1 2026, targeting patients who have failed prior therapies [1][22] Efficacy Results - In cohort 4, 75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90, and 33% achieved IGA 0/1, compared to placebo results of 20%, 0%, and 0% respectively [1][7] - The mean percent reduction in EASI for soquelitinib patients was 72% at day 56, compared to 40% for placebo [5] - Continuous improvement in response was observed from day 28 to day 56, with a statistically significant difference (p=0.035) [9] Safety Profile - No new safety signals were reported; adverse events occurred in 41.7% of soquelitinib patients and 50% of placebo patients, all classified as Grade 1-2 [21] - No severe or serious adverse events were reported during the trial [21] Patient Demographics - Cohort 4 included 12 patients treated with soquelitinib and 12 placebo patients, with 10 evaluable at day 56 [3][4] - 50% of cohort 4 patients had received prior systemic therapies, consistent with the overall cohort data where 35% had prior treatments [3][13] Mechanism of Action - Soquelitinib is believed to act through ITK inhibition, which regulates multiple T cell functional pathways, showing potential for a wide range of inflammatory and immune diseases [1][2][25] - Biomarker data indicated reductions in serum IL-4 and IL-5 cytokines, supporting the drug's mechanism of action [18][19] Future Plans - The upcoming Phase 2 trial will enroll approximately 200 patients and will evaluate different dosing regimens of soquelitinib [22] - The trial aims to further assess the efficacy and safety of soquelitinib in a larger patient population [2][22]